cancer, page-5

this is a good stock, the market has seem to neglect it since the last bio run, but things are getting rosy especially after the new year when revenue starts flowing in. In the short term the pentrix cancer cure should provide catalyst for further share appreciation.

The research so far by ACU and others in cancer field researching their novel approach has been very encouraging to say the least.

Trials are overdue, so expect the sp to rise in anticipation.

Cheers